Literature DB >> 30858207

Evaluation of the Bactericidal Activity of Fosfomycin in Combination with Selected Antimicrobial Comparison Agents Tested against Gram-Negative Bacterial Strains by Using Time-Kill Curves.

Robert K Flamm1, Paul R Rhomberg2, Jill M Lindley2, Kim Sweeney3, E J Ellis-Grosse3, Dee Shortridge2.   

Abstract

The effects of combining fosfomycin with various antimicrobial agents were evaluated in vitro by broth microdilution checkerboard and time-kill kinetic studies. Checkerboard analyses were used to evaluate the following 30 Gram-negative isolates: 5 Pseudomonas aeruginosa, 5 Acinetobacter baumannii-Acinetobacter calcoaceticus species complex, and 20 Enterobacteriaceae isolates. No isolate exhibited antagonism when fosfomycin was tested in combination, and synergy was observed in more than 25% of the drug combinations tested. The most frequent instances of synergy occurred when testing fosfomycin with β-lactams. Two isolates of Pseudomonas aeruginosa, 2 of Klebsiella pneumoniae, and 1 of the A. baumannii-A. calcoaceticus species complex that exhibited synergy when fosfomycin was tested in combination were subjected to time-kill kinetic analyses for confirmation. Time-kill assays confirmed synergistic activity. These data indicated that combination therapy with fosfomycin may be beneficial.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  fosfomycin; synergy

Mesh:

Substances:

Year:  2019        PMID: 30858207      PMCID: PMC6496043          DOI: 10.1128/AAC.02549-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

Review 1.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

2.  Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae.

Authors:  Miao Zhao; Zackery P Bulman; Justin R Lenhard; Michael J Satlin; Barry N Kreiswirth; Thomas J Walsh; Amanda Marrocco; Phillip J Bergen; Roger L Nation; Jian Li; Jing Zhang; Brian T Tsuji
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

3.  Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria.

Authors:  Antonia C Kastoris; Petros I Rafailidis; Evridiki K Vouloumanou; Ioannis D Gkegkes; Matthew E Falagas
Journal:  Eur J Clin Pharmacol       Date:  2010-02-26       Impact factor: 2.953

Review 4.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

5.  In Vitro activities of combinations of rifampin with other antimicrobials against multidrug-resistant Acinetobacter baumannii.

Authors:  Yan Bai; Bin Liu; Tianlin Wang; Yun Cai; Beibei Liang; Rui Wang; Youning Liu; Jin Wang
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

Review 6.  Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections.

Authors:  S S Patel; J A Balfour; H M Bryson
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

7.  Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations.

Authors:  María Díez-Aguilar; María Isabel Morosini; Ana P Tedim; Irene Rodríguez; Zerrin Aktaş; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

8.  Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli.

Authors:  Helio S Sader; Holly K Huynh; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2003-11       Impact factor: 2.803

9.  In vitro and in vivo activity of fosfomycin alone and in combination with rifampin and tigecycline against Gram-positive cocci isolated from surgical wound infections.

Authors:  Oriana Simonetti; Gianluca Morroni; Roberto Ghiselli; Fiorenza Orlando; Andrea Brenciani; Ledia Xhuvelaj; Mauro Provinciali; Annamaria Offidani; Mario Guerrieri; Andrea Giacometti; Oscar Cirioni
Journal:  J Med Microbiol       Date:  2017-11-20       Impact factor: 2.472

10.  In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii.

Authors:  Seongman Bae; Min-Chul Kim; Su-Jin Park; Hee Sueng Kim; Heungsup Sung; Mi-Na Kim; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jun Hee Woo; Yang Soo Kim; Yong Pil Chong
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

View more
  9 in total

1.  In Vitro Pharmacodynamics and Bactericidal Mechanism of Fungal Defensin-Derived Peptides NZX and P2 against Streptococcus agalactiae.

Authors:  Yankang Wu; Na Yang; Ruoyu Mao; Ya Hao; Da Teng; Jianhua Wang
Journal:  Microorganisms       Date:  2022-04-22

2.  Assessment of the in vitro activity of azithromycin niosomes alone and in combination with levofloxacin on extensively drug-resistant Klebsiella pneumoniae clinical isolates.

Authors:  Hoda Mohamed Owais; Manal Mohammad Baddour; Hala Abd El-Raouf El-Metwally; Heba Soliman Barakat; Nour Sherif Ammar; Marwa Ahmed Meheissen
Journal:  Braz J Microbiol       Date:  2021-01-22       Impact factor: 2.476

3.  Synergistic activity of fosfomycin-meropenem and fosfomycin-colistin against carbapenem resistant Klebsiella pneumoniae: an in vitro evidence.

Authors:  Yamuna Devi Bakthavatchalam; Abirami Shankar; Dhiviya Prabaa Muthuirulandi Sethuvel; Kalaiarasi Asokan; Kalaiarasi Kanthan; Balaji Veeraraghavan
Journal:  Future Sci OA       Date:  2020-02-26

4.  Synergistic Microbicidal Effect of Auranofin and Antibiotics Against Planktonic and Biofilm-Encased S. aureus and E. faecalis.

Authors:  Pengfei She; Linying Zhou; Shijia Li; Yiqing Liu; Lanlan Xu; Lihua Chen; Zhen Luo; Yong Wu
Journal:  Front Microbiol       Date:  2019-10-24       Impact factor: 5.640

5.  Synergistic antibacterial effects of colistin in combination with aminoglycoside, carbapenems, cephalosporins, fluoroquinolones, tetracyclines, fosfomycin, and piperacillin on multidrug resistant Klebsiella pneumoniae isolates.

Authors:  Julalak C Ontong; Nwabor F Ozioma; Supayang P Voravuthikunchai; Sarunyou Chusri
Journal:  PLoS One       Date:  2021-01-06       Impact factor: 3.240

6.  Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii: A Prospective, Observational Study.

Authors:  Alessandro Russo; Matteo Bassetti; Valeria Bellelli; Luigi Bianchi; Federica Marincola Cattaneo; Stefania Mazzocchetti; Elena Paciacconi; Fabrizio Cottini; Arcangelo Schiattarella; Giuseppe Tufaro; Francesco Sabetta; Alessandro D'Avino
Journal:  Infect Dis Ther       Date:  2020-10-17

7.  Assessment of In-Vitro Synergy of Fosfomycin with Meropenem, Amikacin and Tigecycline in Whole Genome Sequenced Extended and Pan Drug Resistant Klebsiella Pneumoniae: Exploring A Colistin Sparing Protocol.

Authors:  Manawr Al-Quraini; Meher Rizvi; Zaaima Al-Jabri; Hiba Sami; Muna Al-Muzahmi; Zakariya Al-Muharrmi; Neelam Taneja; Ibrahim Al-Busaidi; Rajeev Soman
Journal:  Antibiotics (Basel)       Date:  2022-01-25

Review 8.  Oral Fosfomycin Formulation in Bacterial Prostatitis: New Role for an Old Molecule-Brief Literature Review and Clinical Considerations.

Authors:  Andrea Marino; Stefano Stracquadanio; Carlo Maria Bellanca; Egle Augello; Manuela Ceccarelli; Giuseppina Cantarella; Renato Bernardini; Giuseppe Nunnari; Bruno Cacopardo
Journal:  Infect Dis Rep       Date:  2022-08-18

9.  Synergistic Activity of Colistin Combined With Auranofin Against Colistin-Resistant Gram-Negative Bacteria.

Authors:  Xiaoxuan Feng; Shuai Liu; Yang Wang; Yulin Zhang; Lingxiao Sun; Haibo Li; Chunlei Wang; Yingmei Liu; Bin Cao
Journal:  Front Microbiol       Date:  2021-06-25       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.